Targeting MDM4 Splicing in Cancers

被引:21
|
作者
Bardot, Boris [1 ]
Toledo, Franck [1 ]
机构
[1] PSL Res Univ, Sorbonne Univ, UPMC Univ Paris 06,Inst Curie,Ctr Rech, CNRS UMR 3244,Genet Suppress Tumorale,Equipe Lab, 26 Rue Ulm, F-75248 Paris 05, France
关键词
MDM4; MDM2; p53; alternative splicing; isoform; PRE-MESSENGER-RNA; THERAPEUTIC TARGET; P53; INHIBITION; BCL-X; DOMAIN; MICE; EXPRESSION; REVEALS; CELLS; GENE;
D O I
10.3390/genes8020082
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
MDM4, an essential negative regulator of the P53 tumor suppressor, is frequently overexpressed in cancer cells that harbor a wild-type P53. By a mechanism based on alternative splicing, the MDM4 gene generates two mutually exclusive isoforms: MDM4-FL, which encodes the full-length MDM4 protein, and a shorter splice variant called MDM4-S. Previous results suggested that the MDM4-S isoform could be an important driver of tumor development. In this short review, we discuss a recent set of data indicating that MDM4-S is more likely a passenger isoform during tumorigenesis and that targeting MDM4 splicing to prevent MDM4-FL protein expression appears as a promising strategy to reactivate p53 in cancer cells. The benefits and risks associated with this strategy are also discussed.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4
    Chandler, Dawn S.
    Singh, Ravi K.
    Caldwell, Lisa C.
    Bitler, Jaquelyn L.
    Lozan, Guillermina
    CANCER RESEARCH, 2006, 66 (19) : 9502 - 9508
  • [22] Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development
    Terzian, Tamara
    Wang, Yongxing
    Van Pelt, Carolyn S.
    Box, Neil F.
    Travis, Elisabeth L.
    Lozano, Guillermina
    MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (15) : 5479 - 5485
  • [23] MiR-370 promotes apoptosis in colon cancer by directly targeting MDM4
    Shen, Xiaogang
    Zuo, Xiaofei
    Zhang, Wenjin
    Bai, Yifeng
    Qin, Xianpeng
    Hou, Nengyi
    ONCOLOGY LETTERS, 2018, 15 (02) : 1673 - 1679
  • [24] Targeting the MDM2/MDM4 Interaction Interface as a Promising Approach for p53 Reactivation Therapy
    Pellegrino, Marsha
    Mancini, Francesca
    Luca, Rossella
    Coletti, Alice
    Giacche, Nicola
    Manni, Isabella
    Arisi, Ivan
    Florenzano, Fulvio
    Teveroni, Emanuela
    Buttarelli, Marianna
    Fici, Laura
    Brandi, Rossella
    Bruno, Tiziana
    Fanciulli, Maurizio
    D'Onofrio, Mara
    Piaggio, Giulia
    Pellicciari, Roberto
    Pontecorvi, Alfredo
    Marine, Jean Christophe
    Macchiarulo, Antonio
    Moretti, Fabiola
    CANCER RESEARCH, 2015, 75 (21) : 4560 - 4572
  • [25] MDM4 (MDMX) and its Transcript Variants
    Mancini, F.
    Di Conza, G.
    Moretti, F.
    CURRENT GENOMICS, 2009, 10 (01) : 42 - 50
  • [26] Mouse models of Mdm2 and Mdm4 and their clinical implications
    Shunbin Xiong
    ChineseJournalofCancer, 2013, 32 (07) : 371 - 375
  • [27] Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2
    Vogel, Simon M.
    Bauer, Matthias R.
    Joerger, Andreas C.
    Wilcken, Rainer
    Brandt, Tobias
    Veprintsev, Dmitry B.
    Rutherford, Trevor J.
    Fersht, Alan R.
    Boeckler, Frank M.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (42) : 16906 - 16910
  • [28] MDM4基因研究进展
    王潇文
    董艳
    卢亦成
    国际遗传学杂志, 2012, (02) : 86 - 90
  • [29] Novel insights about the MDM2/MDM4 heterodimer
    Moretti, Fabiola
    MOLECULAR & CELLULAR ONCOLOGY, 2016, 3 (02)
  • [30] Mouse models of Mdm2 and Mdm4 and their clinical implications
    Xiong, Shunbin
    CHINESE JOURNAL OF CANCER, 2013, 32 (07) : 371 - 375